Zydus Lifesciences inks supply pact with MSN for generic cancer drug in US
.webp)
Zydus Lifesciences Ltd on Friday announced an exclusive licensing and supply agreement with MSN Laboratories for generic cancer treatment drug Cabozantinib tablets, for the US market.
The company's wholly-owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib tablets for the US market, Zydus Lifesciences Ltd said in a regulatory filing.
Cabozantinib tablet is the generic version of CABOMETYX of Exelixis.
Under the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval, the company said.
Zydus will exclusively market, distribute, and sell the product in the US market, it added.
"MSN was a first sole ANDA (abbreviated new drug application) applicant for Cabozantinib tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX, " Zydus Lifesciences said.
Commenting on the partnership, Zydus Lifesciences Managing Director Sharvil Patel said it underscores the company's commitment to provide patients with access to high-quality, affordable medications.
"Cabozantinib tablets are an important treatment option for many cancer patients, and we are pleased to work with MSN to bring the generic version of CABOMETYX to the US market," Patel added.
MSN Group Chairman & Founder Managing Director MSN Reddy said, bringing Cabozantinib tablets to market represents another example of MSN's global development, manufacturing, and regulatory expertise.
"We are confident that working with Zydus will allow us to successfully commercialise Cabozantinib, while advancing our mission of enabling access to high quality, affordable medicines," Reddy added.
Zydus Lifesciences said the total addressable market opportunity of Cabozantinib Tablets in the US is approximately USD 1,464 million as per IQVIA MAT March 2024 data.
Other Latest News
.webp)
The Economic Offences Unit (EOU) of Bihar Police on Thursday arrested four persons, including three from West Bengal, in connection with the constable recruitment examination question paper leak on October 1, 2023, leading to its cancellation by the Central Selection Board of Constables (CSBC) on October 3.
The arrested persons are Kaushik Kumar Kar and Sanjay Das, both residents of North 24 Parganas, West Bengal, and Suman Bishwas from Kolkata. Another arrested person, Saurabh Bandhopadhay, hails from Lucknow, Uttar Pradesh.
.webp)
Six people were injured after a portion of the roof of the Delhi airport's Terminal-1 fell on cars, including taxis, amid heavy rains early Friday, Delhi Fire Services (DFS) officials said.
They said a search operation is underway to make sure no one else is trapped in the damaged vehicles.
Besides the roof sheet, the support beams also collapsed, damaging the cars parked in the pick-up and drop area of the terminal, the officials said.
.webp)
A group of five men pasted posters outside the residence of AIMIM president Asaduddin Owaisi here on Thursday evening, demanding his suspension from the Lok Sabha, officials said.
According to a police officer, four-five men reached Owaisi's 34 Ashoka Road residence located in Central Delhi and pasted three posters at the entry gate and wall of the house about 9 pm.
.webp)
Stocks of small-and-medium enterprises (SME) have seen a good run at the bourses, with select counters surging over 700 per cent thus far in calendar year 2024, shows ACE Equity data. Out of the 192 SME stocks listed on the NSE, 109 stocks, or nearly 57 per cent of the counters have given a positive return during this period, data shows.
Of these 109 SME counters, 65 stocks have given a double-digit return (between 10 per cent and 99 per cent), while 25 stocks have more than doubled in price, i.e. return in excess of 100 per cent.
.webp)
The Securities and Exchange Board of India (Sebi) on Thursday eased the delisting framework to allow promoters a fair shot at taking their companies private. It also revised the eligibility criteria for inclusion and removal of stocks from the futures & options segment to ensure liquid stocks were traded in the segment.
Tightening rules for finfluencers and those doling out stock advice, Sebi barred regulated entities and people from having any association with anyone providing direct or indirect recommendations or claiming guaranteed returns.
.webp)
.webp)
.webp)
.webp)
.webp)
